Exactech obtains FDA approval for Gibralt occipital spine system

7 May 2013 (Last Updated May 7th, 2013 18:30)

Orthopaedic implant devices developer Exactech has obtained the US Food and Drug Administration (FDA) approval for its Gibralt occipital spine system, designed for complex cervical thoracic spine procedures.

Orthopaedic implant devices developer Exactech has obtained the US Food and Drug Administration (FDA) approval for its Gibralt occipital spine system, designed for complex cervical thoracic spine procedures.

Equipped with polyaxial screws and cannulated screws in multiple diameters and lengths, hooks, rods, rod-to-rod connectors, offset connectors and cross connectors, the system is claimed to provide versatility for surgeons during fusion.

Features of the occipital spine system include medial lateral adaptability from 25mm to 45mm, low-profile occipital screws, bend zones for contouring and 360° articulating rods.

"The spine system is designed be configurable to match individual patient anatomy."

The spine system is also designed be configurable to match individual patient anatomy.

Exactech senior vice president and spine division general manager Bruce Thompson said the company is excited to release the final components of the Gibralt system to the market.

"The occipital plate and articulating rods provide surgeons with a comprehensive posterior solution. The Gibralt OCT system provides seamless integration with the Proliant 5.5mm and Hydralok 6.0mm thoraco-lumbar pedicle screw systems," Thompson said.

The approval means the company now provides spinal fusion products for every part of the spine, and is currently in the process of launching the Gibralt system in the US.